Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.49 |
| ▸ | JAK3 | P52333 | 19/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 15/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2230469 | 0.85 | JAK2 (0.47) | JAK2JAK3PTK2 | |
| SCHEMBL2227596 | 0.79 | PSEN1 (0.55) | JAK2JAK3PTK2 | |
| SCHEMBL2229898 | 0.78 | PSEN1 (0.53) | IMPDH2IMPDH1 | |
| SCHEMBL2228593 | 0.74 | PSEN1 (0.51) | JAK2JAK3PTK2 | |
| SCHEMBL12518222 | 0.73 | PSEN1 (0.57) | — | |
| SCHEMBL1360167 | 0.72 | IMPDH2 (0.46) | IMPDH2IMPDH1 | |
| SCHEMBL1358579 | 0.71 | IMPDH2 (0.48) | IMPDH2IMPDH1 | |
| SCHEMBL2227560 | 0.69 | JAK2 (0.53) | JAK2JAK3PTK2 | |
| SCHEMBL13837007 | 0.69 | PSEN1 (0.67) | — | |
| SCHEMBL16418197 | 0.68 | IMPDH2 (0.46) | IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145399-B2 | Substituted bicyclic triazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20120295901-A1 | NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-11-22 | — | — | US | disclosed |
| EP-2523955-A1 | NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceuticals Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086098-A1 | NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295901-A1 | NOVEL SUBSTITUTED BICYCLIC TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | JAK2 4105/4885JAK3 3487/4885PTK2 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.